PMN310 Shows No ARIA Signals in Early Alzheimer’s Phase 1b Trial
PMN310 demonstrates no ARIA signals in Phase 1b trial for early Alzheimer's disease, positioning oligomer-selective targeting as a safer...
Pulse Biosciences Reaches Midpoint in NANOPULSE-AF Ablation Trial
Pulse Biosciences reaches midpoint in NANOPULSE-AF ablation trial for atrial fibrillation, targeting full enrollment by early Q4 2026.
Viking Therapeutics Advances VK2735 Oral Program Into Phase 3 Trials
Viking Therapeutics advances VK2735 into Phase 3 trials with fully enrolled studies and plans for oral formulation testing by...
Grace Therapeutics Receives FDA Type A Meeting Minutes on GTx-104 Resubmission Path
Grace Therapeutics receives FDA Type A meeting minutes outlining the path for GTx-104 resubmission, focusing on manufacturing and packaging...
GLP-1s Are Cutting My AUD Patients’ Hospitalizations. Trial Designers Need to Know Why.
A Lancet Psychiatry study links GLP-1 receptor agonists to fewer AUD and SUD hospitalizations—but the post-discontinuation signal demands a...
Veru Completes Enrollment in Phase 2b PLATEAU Trial of Enobosarm and Semaglutide
Veru completes enrollment in Phase 2b PLATEAU Trial testing enobosarm with semaglutide in older adults with severe obesity.
Oral Semaglutide Shows Reduced Heavy Drinking Days in AUD Trial
Oral semaglutide reduced heavy drinking days and alcohol cravings in an eight-week randomized trial for alcohol use disorder, with...
CLN-049 Advances to Registrational Phase 2 Study in Relapsed/Refractory AML
CLN-049 advances to registrational Phase 2 study in relapsed/refractory AML following FDA's End-of-Phase 1 meeting with Cullinan Therapeutics.
The Genetics Are Global. Your Enrollment Plan Isn’t.
A landmark Lancet Neurology study exposes the operational gap in Parkinson's trials: ancestry-based biomarker screening built for European cohorts...
Atea’s Bemnifosbuvir/Ruzasvir Meets Endpoints in Phase 3 Hepatitis C Trial
Atea's bemnifosbuvir/ruzasvir achieved non-inferiority in Phase 3 Hepatitis C trial, offering eight-week treatment for non-cirrhotic patients versus twelve week